Zacks Investment Research upgraded shares of Neos Therapeutics (NASDAQ:NEOS) from a hold rating to a buy rating in a research report sent to investors on Thursday, Zacks.com reports. The brokerage currently has $1.50 price objective on the stock.

According to Zacks, “Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. “

A number of other research analysts have also recently commented on NEOS. Cantor Fitzgerald reissued an overweight rating and issued a $130.00 target price (up previously from $116.00) on shares of Zoetis in a research note on Wednesday, June 12th. ValuEngine cut Zosano Pharma from a buy rating to a hold rating in a research note on Wednesday, May 1st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. Neos Therapeutics presently has a consensus rating of Hold and a consensus price target of $6.88.

NEOS traded down $0.06 during trading on Thursday, reaching $1.28. The stock had a trading volume of 207,277 shares, compared to its average volume of 435,877. The company has a quick ratio of 1.27, a current ratio of 1.49 and a debt-to-equity ratio of 41.70. Neos Therapeutics has a one year low of $1.13 and a one year high of $6.30. The firm’s 50-day moving average is $1.36.

Neos Therapeutics (NASDAQ:NEOS) last released its earnings results on Thursday, May 9th. The company reported ($0.15) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.07. The firm had revenue of $14.63 million during the quarter, compared to the consensus estimate of $14.20 million. As a group, equities analysts anticipate that Neos Therapeutics will post -0.61 earnings per share for the current year.

Large investors have recently made changes to their positions in the company. BNP Paribas Arbitrage SA grew its stake in shares of Neos Therapeutics by 1,749.5% during the first quarter. BNP Paribas Arbitrage SA now owns 10,098 shares of the company’s stock valued at $26,000 after buying an additional 9,552 shares during the last quarter. Alambic Investment Management L.P. bought a new position in shares of Neos Therapeutics during the first quarter valued at about $32,000. Two Sigma Investments LP bought a new position in shares of Neos Therapeutics during the fourth quarter valued at about $35,000. American International Group Inc. grew its stake in shares of Neos Therapeutics by 63.9% during the fourth quarter. American International Group Inc. now owns 30,814 shares of the company’s stock valued at $51,000 after buying an additional 12,016 shares during the last quarter. Finally, Jane Street Group LLC bought a new position in shares of Neos Therapeutics during the fourth quarter valued at about $62,000. 54.87% of the stock is currently owned by hedge funds and other institutional investors.

Neos Therapeutics Company Profile

Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.

Further Reading: Day Trading – Risk Worth the Reward?

Get a free copy of the Zacks research report on Neos Therapeutics (NEOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.